Christophe Bianchi, M.D., is President of the Takeda Global Oncology Business Unit, a position he has held since October 2014. In his current role, Dr. Bianchi is responsible for oncology business activities in seven countries, including the U.S., Japan, U.K., Germany, France, Brazil and Indonesia. Dr. Bianchi has more than 17 years of pharmaceutical industry experience and has held executive positions with Sanofi-Aventis and Millennium Pharmaceuticals. During his career, he has built commercial and sales organizations, launched major brands, delivered sustained growth and managed collaboration with partner companies. Dr. Bianchi joined Millennium in 2006 where he was responsible for growing the company’s commercial and sales organizations and overseeing all commercial and sales activities for VELCADE®. At Sanofi, Dr. Bianchi led the $2 billion U.S. oncology business unit including Eloxatin® and Taxotere. Previously at Sanofi-Synthelabo, Dr. Bianchi headed the internal medicine and central nervous system business unit with sales of $1.2 billion. Dr. Bianchi also spent more than 10 years at Rhone-Poulenc Rorer, where he last served as Vice President, Head of Global Marketing and led many of the commercial efforts for the antithrombotic, Lovenox®. Dr. Bianchi received his medical degree from the University of Reims-Champagne in France, and an MBA from the Wharton School at the University of Pennsylvania in the U.S.  

 Oncology